Search
micafungin (Mycamine)
Indications:
- candida
- treatment of esophageal candidiasis
- prevention of candidiasis in patients undergoing bone marrow transplantation
- intravascular catheter-related infection due to Candidia [2]
Dosage:
1) IV infusion over 60 minutes
2) esophageal candidiasis: 150 mg QD
3) prophylaxis for bone marrow transplant recipients: 50 mg QD
50 mg lyophilized powder, single-use, in light-protected vials
reconstitue with 5 mg normal saline or 5% dextrose
do NOT shake (excessive foaming)
stable for 24 hours at room temperative after reconstitution
Pharmacokinetics:
- renal clearance
No dosage adjustment for elderly or renal impairment
Adverse effects:
- histamine reaction (urticaria), serious reactions possible
Drug interactions:
- micafungin delays elimination of nifedipine & sirolimus
Laboratory:
- micafungin in serum/plasma
Mechanism of action:
1) an echinocandin antifungal agent similar to caspofungin
- inhibits the synthesis of beta (1,3)-D-glucan, an essential cell-wall component in Candida & Aspergillus
Interactions
drug interactions
General
echinocandin
Properties
MISC-INFO: pregnancy-category C
Database Correlations
PUBCHEM correlations
References
- Prescriber's Letter 12(5): 2005
New Drug: Micafungin (Mycamine)
Detail-Document#: 210509
(subscription needed) http://www.prescribersletter.com
- Medical Knowledge Self Assessment Program (MKSAP) 17,
American College of Physicians, Philadelphia 2015
- http://www.us.astellas.com